Weekly Biotech Buzz: FGEN Cuts Jobs, FDA OKs ADAP's Groundbreaking Cell Therapy, ME Rebuffs CEO Bid

There seems to be no respite from job cuts as several companies announced workforce reductions this week as well. Meanwhile, on the research front, there was a mix of news: encouraging results emerged related to Alzheimer's drug Leqembi and antidiabetic medication Tirzepatide, while a prostate cancer drug trial unfortunately disappointed.

from RTT - Top Story https://ift.tt/JaRPBTF
via IFTTT